A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia in Adult Subjects With Non-Dialysis Dependent Chronic Kidney Disease

Trial Profile

A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia in Adult Subjects With Non-Dialysis Dependent Chronic Kidney Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 04 May 2017

At a glance

  • Drugs Ferric citrate (Primary)
  • Indications Iron deficiency anaemia
  • Focus Therapeutic Use
  • Sponsors Keryx Biopharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 May 2017 According to a Keryx Biopharmaceuticals media release, data from this study was presented at The National Kidney Foundations 2017 Spring Clinical Meetings and at the World Congress of Nephrology (WCN).
    • 04 May 2017 According to a Keryx Biopharmaceuticals media release, the Prescription Drug User Fee Act (PDUFA) target action date for the U.S. FDA was set for 06 November 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top